Literature DB >> 18338744

Molecular basis explanation for imatinib resistance of BCR-ABL due to T315I and P-loop mutations from molecular dynamics simulations.

Tai-Sung Lee1, Steven J Potts, Hagop Kantarjian, Jorge Cortes, Francis Giles, Maher Albitar.   

Abstract

BACKGROUND: Computational simulations have become powerful tools for understanding detailed interactions in biologic systems. To the authors' knowledge to date, the mechanism of imatinib resistance in BCR-ABL has not been clarified at the atomic level, and computational studies are required.
METHODS: Molecular dynamics (MD) simulations on the complex of imatinib with the wild-type, T315I mutant, and 10 other P-loop mutants of the tyrosine kinase BCR-ABL were performed to study the mechanism of imatinib resistance.
RESULTS: Simulations suggested that imatinib resistance of T315I results mainly comes from the breakdown of interactions between imatinib and both E286 and M290, contradictory to what was believed previously, in that the missing hydrogen bonding is the main contribution. The current results also demonstrated that the unfavorable electrostatic interaction between P-loop and imatinib is the main reason for resistance for the P-loop mutations. Furthermore, in Y253H, protonation of the histidine at the epsilon position is essential for rendering this mutation resistant to imatinib.
CONCLUSIONS: The current results indicated that large-scale simulations may offer insight and information that other simple modeling methods cannot provide regarding the problem of BCR-ABL imatinib resistance, especially in the case of conformational changes because of remote mutations. Imatinib resistance mechanisms that were not anticipated previously were revealed by analyzing the interactions between imatinib and individual residues based on simulation results. This results demonstrated that MD is a powerful way to verify and predict the clinical response or resistance to imatinib and to other potential drugs.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18338744     DOI: 10.1002/cncr.23355

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  15 in total

1.  Computational modeling of structurally conserved cancer mutations in the RET and MET kinases: the impact on protein structure, dynamics, and stability.

Authors:  Anshuman Dixit; Ali Torkamani; Nicholas J Schork; Gennady Verkhivker
Journal:  Biophys J       Date:  2009-02       Impact factor: 4.033

Review 2.  Mechanisms of drug resistance in kinases.

Authors:  Rina Barouch-Bentov; Karsten Sauer
Journal:  Expert Opin Investig Drugs       Date:  2011-02       Impact factor: 6.206

3.  Ensemble-based virtual screening: identification of a potential allosteric inhibitor of Bcr-Abl.

Authors:  Vivek Kumar Singh; Mohane Selvaraj Coumar
Journal:  J Mol Model       Date:  2017-07-01       Impact factor: 1.810

4.  Computational analysis of the binding specificity of Gleevec to Abl, c-Kit, Lck, and c-Src tyrosine kinases.

Authors:  Yen-Lin Lin; Benoît Roux
Journal:  J Am Chem Soc       Date:  2013-09-20       Impact factor: 15.419

5.  Molecular mechanisms of acquired resistance to tyrosine kinase targeted therapy.

Authors:  J Rafael Sierra; Virna Cepero; Silvia Giordano
Journal:  Mol Cancer       Date:  2010-04-12       Impact factor: 27.401

6.  Explaining why Gleevec is a specific and potent inhibitor of Abl kinase.

Authors:  Yen-Lin Lin; Yilin Meng; Wei Jiang; Benoît Roux
Journal:  Proc Natl Acad Sci U S A       Date:  2013-01-14       Impact factor: 11.205

7.  Irreversible inhibitors of c-Src kinase that target a nonconserved cysteine.

Authors:  Frank E Kwarcinski; Christel C Fox; Michael E Steffey; Matthew B Soellner
Journal:  ACS Chem Biol       Date:  2012-09-05       Impact factor: 5.100

8.  A conserved salt bridge in the G loop of multiple protein kinases is important for catalysis and for in vivo Lyn function.

Authors:  Rina Barouch-Bentov; Jianwei Che; Christian C Lee; Yating Yang; Ann Herman; Yong Jia; Anastasia Velentza; James Watson; Luise Sternberg; Sunjun Kim; Niusha Ziaee; Andrew Miller; Carie Jackson; Manabu Fujimoto; Mike Young; Serge Batalov; Yi Liu; Markus Warmuth; Tim Wiltshire; Michael P Cooke; Karsten Sauer
Journal:  Mol Cell       Date:  2009-01-16       Impact factor: 17.970

9.  An in silico study of the molecular basis of B-RAF activation and conformational stability.

Authors:  Filip F Fratev; Svava Osk Jónsdóttir
Journal:  BMC Struct Biol       Date:  2009-07-22

10.  Molecular interactions of c-ABL mutants in complex with imatinib/nilotinib: a computational study using linear interaction energy (LIE) calculations.

Authors:  Elen Gomes Pereira; Miguel Angelo Martins Moreira; Ernesto Raúl Caffarena
Journal:  J Mol Model       Date:  2012-05-09       Impact factor: 1.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.